BlackRock Inc. grew its holdings in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 8.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,064,259 shares of the biopharmaceutical company’s stock after buying an additional 736,608 shares during the quarter. BlackRock Inc. owned 5.96% of Immunomedics worth $146,478,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Calton & Associates Inc. purchased a new stake in Immunomedics during the fourth quarter worth approximately $135,000. SG Americas Securities LLC grew its stake in Immunomedics by 27.2% during the third quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 5,631 shares during the period. Teacher Retirement System of Texas purchased a new stake in Immunomedics during the fourth quarter worth approximately $524,000. Hussman Strategic Advisors Inc. purchased a new stake in Immunomedics during the fourth quarter worth approximately $808,000. Finally, American International Group Inc. grew its stake in Immunomedics by 8.1% during the third quarter. American International Group Inc. now owns 68,533 shares of the biopharmaceutical company’s stock worth $958,000 after buying an additional 5,125 shares during the period. Institutional investors own 74.51% of the company’s stock.
In other news, Director David M. Goldenberg sold 17,729 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $17.09, for a total value of $302,988.61. Following the completion of the transaction, the director now directly owns 1,774,285 shares in the company, valued at $30,322,530.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Goldenberg sold 20,000 shares of the stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total transaction of $350,000.00. Following the transaction, the director now owns 1,774,285 shares in the company, valued at $31,049,987.50. The disclosure for this sale can be found here. Insiders sold 77,729 shares of company stock valued at $1,342,589 over the last 90 days. Insiders own 14.80% of the company’s stock.
Immunomedics stock opened at $15.37 on Thursday. The firm has a market cap of $2,571.15, a price-to-earnings ratio of -7.61 and a beta of 1.48. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 1.20. Immunomedics, Inc. has a 52 week low of $5.00 and a 52 week high of $18.93.
Immunomedics (NASDAQ:IMMU) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. analysts anticipate that Immunomedics, Inc. will post -0.96 EPS for the current fiscal year.
Several research firms have issued reports on IMMU. BidaskClub downgraded shares of Immunomedics from a “buy” rating to a “hold” rating in a research note on Saturday, March 17th. Zacks Investment Research downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Jefferies Group upped their target price on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $19.00.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/22/blackrock-inc-grows-holdings-in-immunomedics-inc-immu.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.